Neurodegeneration is an incurable, debilitating process which presents a growing global challenge due to our ageing population.
The European-funded project NeuroMET aims to develop a clinical and metrological framework to address the major patient needs, including earlier and more accurate diagnosis, more effective treatment and improved disease progression monitoring. This will be achieved though the development of diagnostic protocols, reference methods and the validation of patient centre outcome measures.
NeuroMET will work closely with clinical laboratories, hospitals and biopharmaceutical companies to ensure the effective exploitation of this project for the benefit of patients.
Alzheimer’s disease and Parkinson’s disease are two of the most common neurodegenerative diseases that both involve the build-up of specific proteins in the brain and the destruction of brain cells. This leads to physical and mental impairment such as dementia, a condition that affects over 46 million people globally and costs around $800 billion per year in social and medical care. This represents a significant and growing problem for health care systems.
Early diagnosis of Alzheimer’s and Parkinson’s are essential for the success of their treatment and potential cure. However, there are currently no minimally invasive diagnostic tools which enable early diagnosis or effective monitoring of the progression of the disease within patients.
will address this challenge.
For further detail on this project download the publishable summary.
The consortium delivering NeuroMET
brings together 9 partners from 5 countries across the EC with support from Parkinsons UK and the International Federation of Clinical Chemistry (IFCC).
It consists of:
- five National Measurements Institutes/Designated Institutes (LGC, INRIM, LNE, PTB, SP)
- two universities (UCL, UEA)
- two hospitals (Charité, Centre Hospitalier Universitaire Montpellier)
To find out more about this project email us.
Log-in to the NeuroMET Sharepoint site.